RPS6KB1 and neoplasm: We have when performed genome-wide comparison of S6K1 and S6K2 positive tumours as well as in breast cancer cells after S6K1 or S6K2 in vitro silencing, revealed major significant differences supporting that these tumours should in part be considered as clinically different groups.